Reported Earnings • Aug 13
First quarter 2027 earnings released: EPS: ₹5.89 (vs ₹1.49 loss in 1Q 2026) First quarter 2027 results: EPS: ₹5.89 (up from ₹1.49 loss in 1Q 2026). Revenue: ₹6.48b (up 23% from 1Q 2026). Net income: ₹414.7m (up ₹519.4m from 1Q 2026). Profit margin: 6.4% (up from net loss in 1Q 2026). Over the last 3 years on average, earnings per share has increased by 116% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Annuncio • Jul 28
Unichem Laboratories Limited to Report Q1, 2027 Results on Aug 11, 2026 Unichem Laboratories Limited announced that they will report Q1, 2027 results on Aug 11, 2026 Board Change • Jul 13
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Chairman Prakash Mody is the most experienced director on the board, commencing their role in 1974. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to ₹639, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 66% over the past three years. New Risk • Jul 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Large one-off items impacting financial results. Reported Earnings • Jul 05
Full year 2026 earnings released Full year 2026 results: Revenue: ₹22.0b (up 4.3% from FY 2025). Net income: ₹2.53b (up 84% from FY 2025). Profit margin: 12% (up from 6.5% in FY 2025). Annuncio • Jun 10
Unichem Laboratories Limited, Annual General Meeting, Aug 11, 2026 Unichem Laboratories Limited, Annual General Meeting, Aug 11, 2026. Valuation Update With 7 Day Price Move • Jun 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹437, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 18% over the past three years. Reported Earnings • May 23
Full year 2026 earnings released: EPS: ₹35.91 (vs ₹19.53 in FY 2025) Full year 2026 results: EPS: ₹35.91 (up from ₹19.53 in FY 2025). Revenue: ₹22.6b (up 7.3% from FY 2025). Net income: ₹2.53b (up 84% from FY 2025). Profit margin: 11% (up from 6.5% in FY 2025). Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Annuncio • May 06
Unichem Laboratories Limited to Report Q4, 2026 Results on May 22, 2026 Unichem Laboratories Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 22, 2026 Reported Earnings • Feb 06
Third quarter 2026 earnings released: EPS: ₹37.54 (vs ₹8.22 in 3Q 2025) Third quarter 2026 results: EPS: ₹37.54 (up from ₹8.22 in 3Q 2025). Revenue: ₹5.33b (flat on 3Q 2025). Net income: ₹2.64b (up 357% from 3Q 2025). Profit margin: 50% (up from 11% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹430, the stock trades at a trailing P/E ratio of 34.2x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 31% over the past three years. Annuncio • Jan 09
Unichem Laboratories Limited to Report Q3, 2026 Results on Feb 05, 2026 Unichem Laboratories Limited announced that they will report Q3, 2026 results on Feb 05, 2026 Reported Earnings • Nov 12
Second quarter 2026 earnings released: ₹1.69 loss per share (vs ₹4.34 profit in 2Q 2025) Second quarter 2026 results: ₹1.69 loss per share (down from ₹4.34 profit in 2Q 2025). Revenue: ₹6.00b (up 30% from 2Q 2025). Net loss: ₹118.9m (down 139% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Annuncio • Oct 15
Unichem Laboratories Limited to Report Q2, 2026 Results on Nov 11, 2025 Unichem Laboratories Limited announced that they will report Q2, 2026 results on Nov 11, 2025 Annuncio • Jul 15
Unichem Laboratories Limited to Report Q1, 2026 Results on Aug 04, 2025 Unichem Laboratories Limited announced that they will report Q1, 2026 results on Aug 04, 2025 Reported Earnings • Jul 09
Full year 2025 earnings released: EPS: ₹19.53 (vs ₹13.32 loss in FY 2024) Full year 2025 results: EPS: ₹19.53 (up from ₹13.32 loss in FY 2024). Revenue: ₹21.1b (up 18% from FY 2024). Net income: ₹1.38b (up ₹2.31b from FY 2024). Profit margin: 6.5% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Post-clinical trial products Approved (during full year): 4 Launched (during full year): 6 Over the last 3 years on average, earnings per share has increased by 27% per year whereas the company’s share price has increased by 32% per year. Annuncio • Jun 20
Unichem Laboratories Limited, Annual General Meeting, Aug 04, 2025 Unichem Laboratories Limited, Annual General Meeting, Aug 04, 2025, at 15:00 Indian Standard Time. Reported Earnings • May 23
Full year 2025 earnings released: EPS: ₹19.53 (vs ₹10.01 loss in FY 2024) Full year 2025 results: EPS: ₹19.53 (up from ₹10.01 loss in FY 2024). Revenue: ₹21.5b (up 26% from FY 2024). Net income: ₹1.38b (up ₹2.08b from FY 2024). Profit margin: 6.4% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • May 10
Unichem Laboratories Limited to Report Q4, 2025 Results on May 22, 2025 Unichem Laboratories Limited announced that they will report Q4, 2025 results on May 22, 2025 Reported Earnings • Feb 07
Third quarter 2025 earnings released: EPS: ₹8.22 (vs ₹11.93 in 3Q 2024) Third quarter 2025 results: EPS: ₹8.22 (down from ₹11.93 in 3Q 2024). Revenue: ₹5.47b (up 26% from 3Q 2024). Net income: ₹578.5m (down 31% from 3Q 2024). Profit margin: 11% (down from 19% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings. Annuncio • Jan 14
Unichem Laboratories Limited to Report Q3, 2025 Results on Feb 06, 2025 Unichem Laboratories Limited announced that they will report Q3, 2025 results on Feb 06, 2025 Reported Earnings • Nov 14
Second quarter 2025 earnings released: EPS: ₹4.34 (vs ₹3.48 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹4.34 (up from ₹3.48 loss in 2Q 2024). Revenue: ₹4.71b (up 13% from 2Q 2024). Net income: ₹304.9m (up ₹549.8m from 2Q 2024). Profit margin: 6.5% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 64% per year, which means it is well ahead of earnings. Annuncio • Oct 25
Unichem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024 Unichem Laboratories Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Annuncio • Jul 26
Unichem Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024 Unichem Laboratories Limited announced that they will report Q1, 2025 results on Aug 08, 2024 Board Change • Jul 17
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Arun Todarwal was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 12
Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023) Full year 2024 results: ₹10.01 loss per share (improved from ₹28.72 loss in FY 2023). Revenue: ₹17.0b (up 27% from FY 2023). Net loss: ₹704.7m (loss narrowed 65% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance. Annuncio • Jun 29
Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024 Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024, at 14:00 Indian Standard Time. Annuncio • Jun 06
Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd Axsome Therapeutics, Inc. announced that it has entered into a settlement agreement with Unichem Laboratories Ltd. (Unichem) resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Unichem of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic equivalent of Sunosi in the United States. The settlement agreement permits Unichem to begin selling its generic version of Sunosi on June 30, 2042, or earlier under certain circumstances. The June 30, 2042 date is also subject to potential extension for pediatric exclusivity. As required by law, Axsome and Unichem will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by Axsome against other parties remains pending in the U.S. District Court for the District of New Jersey. Annuncio • May 31
Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024 Unichem Laboratories Limited announced that Mr. Sandip Ghume, Deputy Chief Financial Officer (KMP) resigned due to personal reasons. Date of cessation: June 30, 2024. The Company has accepted his resignation and will be relieved from his duties, effective June 30, 2024. Reported Earnings • May 23
Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023) Full year 2024 results: ₹10.01 loss per share (improved from ₹28.72 loss in FY 2023). Revenue: ₹17.4b (up 29% from FY 2023). Net loss: ₹704.7m (loss narrowed 65% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance. New Risk • May 23
New major risk - Revenue and earnings growth Earnings have declined by 37% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Annuncio • May 11
Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024 Unichem Laboratories Limited announced that they will report Q4, 2024 results on May 22, 2024 Reported Earnings • Feb 06
Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023) Third quarter 2024 results: EPS: ₹11.93 (up from ₹9.08 loss in 3Q 2023). Revenue: ₹4.46b (up 47% from 3Q 2023). Net income: ₹839.9m (up ₹1.48b from 3Q 2023). Profit margin: 19% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance. Annuncio • Jan 16
Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024 Unichem Laboratories Limited announced that they will report Q3, 2024 results on Feb 05, 2024 Annuncio • Jan 12
Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg Unichem Laboratories Limited announced that it has received ANDA approval for its Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Cardura®? (Doxazosin) Tablets, 1 mg, 4 mg and 8 mg. Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. The product will be commercialized from Unichem's Goa Plant. Reported Earnings • Nov 02
Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023) Second quarter 2024 results: ₹3.48 loss per share (improved from ₹10.04 loss in 2Q 2023). Revenue: ₹4.21b (up 28% from 2Q 2023). Net loss: ₹244.9m (loss narrowed 65% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 122 percentage points per year, which is a significant difference in performance. Annuncio • Oct 19
Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023 Unichem Laboratories Limited announced that they will report Q2, 2024 results on Nov 01, 2023 Annuncio • Aug 22
Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023 Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023, at 11:00 Indian Standard Time. Recent Insider Transactions • Aug 19
Insider recently sold ₹12m worth of stock On the 14th of August, Dilip Kunkolienkar sold around 30k shares on-market at roughly ₹404 per share. This transaction amounted to 74% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹47m more than they bought in the last 12 months. Annuncio • Aug 10
Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors Unichem Laboratories Limited announced that at the board meeting held on August 4, 2023, the company noted the Resignation of Mr. Dilip Kunkolienkar (Director Technical) with effect from the close of business hours on August 9, 2023. Consequently, he shall also cease to be a Member of the Audit Committee and Risk Management Committee of the Board of Directors. Further, he has declared and confirmed that there is no other material reason for his resignation as a director. Mr. Kunkolienkar's resignation letter is enclosed herewith. Recent Insider Transactions • Jul 24
Insider recently sold ₹1.5m worth of stock On the 20th of July, Vera Mahajan sold around 4k shares on-market at roughly ₹377 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹10m. Insiders have been net sellers, collectively disposing of ₹15m more than they bought in the last 12 months. Reported Earnings • Jul 15
First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023) First quarter 2024 results: ₹0.09 loss per share (improved from ₹3.32 loss in 1Q 2023). Revenue: ₹4.32b (up 40% from 1Q 2023). Net loss: ₹6.68m (loss narrowed 97% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Jun 02
Non-Executive Independent Director recently sold ₹10m worth of stock On the 29th of May, Prafull Shah sold around 27k shares on-market at roughly ₹374 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Reported Earnings • May 24
Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022) Full year 2023 results: ₹28.72 loss per share (down from ₹4.70 profit in FY 2022). Revenue: ₹13.8b (up 8.8% from FY 2022). Net loss: ₹2.02b (down ₹2.35b from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings. Reported Earnings • Feb 07
Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022) Third quarter 2023 results: ₹9.08 loss per share (further deteriorated from ₹2.01 loss in 3Q 2022). Revenue: ₹3.19b (up 2.4% from 3Q 2022). Net loss: ₹639.3m (loss widened 353% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings. Annuncio • Jan 31
Krka Reportedly Eyes Promoter Stake in Unichem Laboratories Krka, d. d. (LJSE:KRKG) is in discussions to acquire the promoter’s stake in Mumbai-based Unichem Laboratories Limited (BSE:506690), said two people aware of the development. Promoter Prakash Amrut Mody & family owns a 50.93% stake in the listed entity. An acquisition of this stake will trigger an open offer for an additional 26% of equity. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Director of Technical & Whole-Time Director Dilip Kunkolienkar was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022) Second quarter 2023 results: ₹10.04 loss per share (further deteriorated from ₹1.82 loss in 2Q 2022). Revenue: ₹3.38b (up 16% from 2Q 2022). Net loss: ₹706.7m (loss widened 451% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Jul 25
Upcoming dividend of ₹4.00 per share Eligible shareholders must have bought the stock before 01 August 2022. Payment date: 20 August 2022. Payout ratio is on the higher end at 85% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.0%). Reported Earnings • Jul 14
Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021) Full year 2022 results: EPS: ₹4.70 (down from ₹4.88 in FY 2021). Revenue: ₹12.7b (up 2.8% from FY 2021). Net income: ₹330.6m (down 3.7% from FY 2021). Profit margin: 2.6% (down from 2.8% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Approved (during full year): 5 Launched (during full year): 7 Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 29
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: ₹4.70 (down from ₹4.88 in FY 2021). Revenue: ₹13.2b (up 6.7% from FY 2021). Net income: ₹330.6m (down 3.7% from FY 2021). Profit margin: 2.5% (down from 2.8% in FY 2021). Revenue missed analyst estimates by 50%. Earnings per share (EPS) exceeded analyst estimates by 1,721%. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Director of Technical & Whole-Time Director Dilip Kunkolienkar was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jan 30
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: ₹2.01 loss per share (down from ₹3.35 profit in 3Q 2021). Revenue: ₹3.26b (flat on 3Q 2021). Net loss: ₹141.0m (down 160% from profit in 3Q 2021). Revenue missed analyst estimates by 50%. Earnings per share (EPS) were also behind analyst expectations. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 07
Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹2.93b (down 7.6% from 2Q 2021). Net loss: ₹128.2m (down 247% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jul 15
Upcoming dividend of ₹4.00 per share Eligible shareholders must have bought the stock before 22 July 2021. Payment date: 30 August 2021. Trailing yield: 1.2%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.7%). Reported Earnings • Jul 06
Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹12.4b (up 12% from FY 2020). Net income: ₹343.2m (up ₹945.1m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Post-clinical trial products Approved (during full year): 9 Launched (during full year): 10 Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 30
Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹12.4b (up 2.0% from FY 2020). Net income: ₹343.2m (up ₹945.1m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Apr 04
Insider recently bought ₹2.3m worth of stock On the 31st of March, Vidhya Anantharamam bought around 7k shares on-market at roughly ₹311 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Is New 90 Day High Low • Feb 25
New 90-day high: ₹332 The company is up 30% from its price of ₹255 on 27 November 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Feb 02
New 90-day high: ₹295 The company is up 23% from its price of ₹239 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Reported Earnings • Feb 01
Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹3.42b (up 15% from 3Q 2020). Net income: ₹235.6m (up ₹381.6m from 3Q 2020). Profit margin: 6.9% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 15
New 90-day high: ₹286 The company is up 16% from its price of ₹246 on 16 October 2020. The Indian market is up 26% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 11% over the same period. Is New 90 Day High Low • Dec 07
New 90-day high: ₹285 The company is up 17% from its price of ₹243 on 08 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Nov 05
New 90-day low: ₹239 The company is down 8.0% from its price of ₹260 on 07 August 2020. The Indian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Reported Earnings • Nov 04
Second quarter 2021 earnings released: EPS ₹1.24 The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹3.18b (up 7.4% from 2Q 2020). Net income: ₹87.4m (up ₹309.5m from 2Q 2020). Profit margin: 2.8% (up from net loss in 2Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 6% per year. Reported Earnings • Nov 01
First half earnings released Over the last 12 months the company has reported total losses of ₹206.1m, with earnings decreasing by ₹255.0m from the prior year. Total revenue was ₹12.8b over the last 12 months, largely unchanged from the prior year.